Vivus, Inc., the developer of Qnexa, also announced last week that the FDA has accepted for filing and review the New Drug Application for Qnexa for the treatment of obesity. The FDA is expected to make a decision on the application next April.
Approval of Qnexa would make it the only prescription appetite suppressant available in the United States. Previous drugs in this class have been approved, but later withdrawn after reports of serious side effects. Read more in Psychiatric News.